Original Article
Analysis on the effects of different immunization schedules after the conversion of polio vaccine immunization strategy
Chen Qiang, Leng Hongying, Qi Yuhua, Jiang Tongkang, Guo Hongxiong
Published 2022-12-30
Cite as Chinese J Exp Clin Virol, 2022, 36(6): 637-643. DOI: 10.3760/cma.j.cn112866-20220621-00138
Abstract
ObjectiveTo analyze immune effects of children with different immunization schedules after the conversion of polio vaccine immunization strategy.
MethodsSerum samples of children with different immunization schedules were collected in 2018 and 2021 respectively. The neutralizing antibody against poliovirus was detected by micro cell neutralization test, and the antibody positive rate and geometric mean titer (GMT) were analyzed.
ResultsThe positive rates of neutralizing antibodies against type I and type III poliovirus in children immunized with two doses inactivated polio vaccine (IPV) and two doses bivalent live attenuated oral polio vaccine (bOPV), one dose IPV and 3 doses bOPV were both 100.00%. The GMT for type I poliovirus antibody were higher than 1∶300, and for type III poliovirus antibody were close to 1∶200. In children vaccinated with IPV, the positive rates of type I and III poliovirus antibodies were 96.72% and 95.08%, and the GMT for type I and III poliovirus antibodies were 1∶96.72 and 1∶48.72, respectively. In children vaccinated with trivalent live attenuated oral polio vaccine (tOPV) only, the positive rates of type I and III poliovirus antibodies were 98.68% and 96.05%, and the GMT for type I and III poliovirus antibodies were 1∶126.84 and 1∶68.22, respectively. In children vaccinated with three doses tOPV and one dose bOPV, the positive rates of type I and III poliovirus antibodies were 100.00% and 98.57%, and the GMT for type I and III poliovirus antibodies were 1∶214.21 and 1∶94.17, respectively.
ConclusionsChildren who received sequential immunization with IPV and live attenuated oral polio vaccine (OPV) have a high level of positive rate and GMT of neutralizing antibody against poliovirus type I and III.
Key words:
Polio vaccine; Immunization strategy; Neutralizing antibody
Contributor Information
Chen Qiang
Jiangsu Provincial Center f or Disease Control and Prevention, Nanjing 210009, China
Leng Hongying
Jiangsu Provincial Center f or Disease Control and Prevention, Nanjing 210009, China
Qi Yuhua
Jiangsu Provincial Center f or Disease Control and Prevention, Nanjing 210009, China
Jiang Tongkang
Jiangsu Provincial Center f or Disease Control and Prevention, Nanjing 210009, China
Guo Hongxiong
Jiangsu Provincial Center f or Disease Control and Prevention, Nanjing 210009, China
